A Phase I, Open-Label, Study of the Safety, Pharmacokinetics, and Pharmacodynamics Dose Escalation of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Pazopanib (Primary) ; Doxorubicin; Epirubicin
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.